Vanderbilt University School of Medicine Academy for Excellence in Clinical Medicine (AECM) has selected 25 new members.

Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer. Which patients will benefit the most, however, remains unclear; current biomarkers such as PD-L1 that are used to predict response are mediocre at best.

Vanderbilt researchers are bolstering the fight against cancer with technology that enhances the effectiveness of T cells that attack tumors.

Tuya Pal, MD, Ingram Professor of Cancer Research and associate director for Cancer Health Disparities at Vanderbilt-Ingram Cancer Center, has been named to two cancer research leadership posts.

After serving as interim director since Jan. 1, Ben Ho Park, MD, PhD, Donna S. Hall Professor of Breast Cancer Research at Vanderbilt University Medical Center, has been named director of the Division of Hematology and Oncology.

Continuous activation of cell surface receptors increases signaling that can promote oncogenic transformation. One receptor, EphA2, has been identified as a driver of lung cancer, but its interacting partners are not well characterized.

Two Vanderbilt-Ingram Cancer Center investigators have received financial support from Susan G. Komen for breast cancer research.

Vanderbilt-Ingram Cancer Center's Justin Balko, PharmD, PhD, has received a $100,000 research grant from the Mary Kay Foundation.

Testing for all metastatic breast cancer patients may be an optimal strategy for identifying additional patients with increased risk as well as response to targeted therapies.

Breast cancer researchers at Vanderbilt-Ingram Cancer Center have secured a fourth round of continuous Specialized Program of Research Excellence funding.